Prescription drug use often depends on "affordability"; true for 1 in 4 lower income patients with late-stage cancer
- Affordability (20%)
- Patient does not feel they need the medication (20%)
- Side effects (17%)
- Forgetfulness (16%)
- Lack of concern for their condition (5%)
- Lack of information on disease or treatment (5%)
- Lack of information on the drug they are prescribed (5%)
- Lack of family/social support (5%)
- Low satisfaction with the drug they are prescribed (3%)
- Poor relationship with myself or another physician (2%)
- Patient received prior recommendation against the drug either by another health professional or patient (2%).
Two-thirds of physicians believe that they have the most influence of whether patients take medications as prescribed; 30% believe that the caregivers have more influence. 6% believe it's the health plan that wields the most influence over prescription adherence.
If you think patients are dissing prescriptions only for asymptomatic conditions like high blood pressure, you're dead wrong.
The Rx "affordability" hurdle is demonstrated by new data released by Thomson Reuters, which has found that some cancer patients avoid treatment due to cost. According to Thomson, 25% of patients with late-stage cancer whose incomes are under $40,000 choose not to undergo recommended care.
In their report, The Cost of Cancer, Thomson analyzes 1,767 survey responses completed by cancer patients. Thomson identifies what they term "a clear link" between income and the acquisition of cancer treatment.
The difference between patients of varying income levels is striking: overall, 12.3% of late-stage cancer patients refuse cancer treatment due to its expense. By income level:
- 25% of late-stage cancer patients who earn less than $40,000 a year choose not to undergo a recommended treatment due to cost
- 11% of those earning between $40,000 and $80,000 per year refuse treatment
- 5% those earning more than $80,000 annually refuse treatment for cancer.
Health Populi's Hot Points: Last November, Highmark, the Blues plan in Pittsburgh, began to offer what it marketed as "the ultimate get-well card:" a debit card for health expenses.
Archstone also sees that, "Consumers are gravitating toward cards that allow them the flexibility to purchase household needs at the gas station, supermarket, or pharmacy," according to their research.


2 Comments:
"The difference between patients of varying income levels is striking: overall, 12.3% of late-stage cancer patients refuse cancer treatment due to its expense."
My question would be whether this was due to a perception by the patient that they were terminal anyway and that the treatments were only slightly prolonging the inevitable. If so, they may conclude that they do not wish to impose this cost on themselves, their families, insurers, or taxpayers to what they see as a futile expense. For example, I could see myself passing up expensive treatment options that ultimately did me no real good (simply bought a few more days of life in a hospital bed) and imposed great costs upon myself and others.
I would feel the same way about spending my final days hooked up to machines in an ICU. Why create the expense when it doen't return me to health and serves only to prolong dying?
By
Anonymous, At
October 15, 2008 10:35 AM
Jane's juxtaposition of our Health Engagement Barometer with The Center's "How Engaged Are Consumers in Their Health and Health Care, and Why Does It Matter." The strong, direct relationship that the Center's study shows between patient confidence in being well-informed and their activation in managing their health is powerful and shows why both our (Edelman's) study and the Center's show that effective health engagement by individuals is essential. And if I can just add: defining individuals as "people" not just "patients" will help us think in the ways we have to move the mark.
By
Nancy Turett, At
October 18, 2008 12:47 PM
Post a Comment
<< Home